CHMP recommends approval for Averoa’s Xoanacyl, an oral therapy for chronic kidney disease: Grenoble, France Friday, April 4, 2025, 12:00 Hrs [IST] Averoa, a biopharmaceutical c ...
Therapeutics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a ...
Averoa, a biopharmaceutical company bringing innovative therapeutic solutions to people with renal diseases, today announces a positive opinion from the European Medicines Agency (EMA)’s Committee for ...
CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and ...
A “Strong Buy” rating from Wall Street indicates that analysts believe a stock has the potential for future price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback